Royalty Pharma's Recent Dividend Announcement
The board of directors of Royalty Pharma plc (NASDAQ: RPRX) has decided to declare a dividend for the third quarter of the year 2025. This dividend is set at $0.22 per Class A ordinary share, which reflects the company’s consistent commitment to rewarding its shareholders.
Dividend Payment Dates
This dividend is scheduled to be paid on September 10, 2025, to shareholders who are on record by the close of business on August 15, 2025. This timeline ensures that eligible investors can benefit from the dividend payout during this period.
About Royalty Pharma
Established in 1996, Royalty Pharma has emerged as the largest purchaser of biopharmaceutical royalties worldwide. The company is committed to fostering innovation throughout the biopharmaceutical field. By collaborating with a broad range of innovators, including universities, research hospitals, and biotechnology firms, Royalty Pharma has built an impressive portfolio of royalty rights on many leading therapies.
Portfolio Highlights
Royalty Pharma's portfolio currently includes royalties from over 35 commercial products. This includes notable drugs like Vertex's Trikafta, which has significantly transformed care for cystic fibrosis patients, and GSK's Trelegy, a triple-combination inhaler for chronic obstructive pulmonary disease (COPD). Additionally, the portfolio features Roche's Evrysdi, Johnson & Johnson's Tremfya, and Biogen's Tysabri and Spinraza, among others.
Funding Innovation
Royalty Pharma is not only involved in acquiring existing royalties but also actively participates in creating new opportunities. The company partners with biopharmaceutical developers to co-fund late-stage clinical trials and new product launches, with the expectation of receiving future royalties. This business model allows them to support innovative treatments while also ensuring rewarding returns for their investors.
Investor Relations Contact Information
Royalty Pharma encourages interested parties to reach out for investor relations inquiries. The contact number for investor relations is +1 (212) 883-6637. Investors can also contact the company via email at ir@royaltypharma.com.
Frequently Asked Questions
What is the dividend amount declared by Royalty Pharma?
Royalty Pharma has declared a dividend of $0.22 per Class A ordinary share for the third quarter of 2025.
When will the dividend be paid?
The dividend is set to be paid on September 10, 2025, to eligible shareholders.
When is the record date for the dividend?
The record date for this dividend payment is August 15, 2025.
What is the primary focus of Royalty Pharma?
Royalty Pharma is focused on purchasing biopharmaceutical royalties and funding innovations within the biopharmaceutical industry.
How can investors contact Royalty Pharma for inquiries?
Investors can contact Royalty Pharma at +1 (212) 883-6637 or via email at ir@royaltypharma.com.
